Significance of neutrophil-to-lymphocyte ratio, 1 platelet-to-lymphocyte ratio for predicting clinical outcomes in 2 COVID-19 3 Shaoping Huang¹, Min Liu¹, Xiaolu Li², Zhiyin Shang¹, Ting Zhang^{2*}, 4 Hongzhou Lu^{1*} 5 6 Author Affiliations: ¹Shanghai Public Health Clinical Center, Fudan University, 7 Shanghai 201508, China; ² Department of Gastroenterology, Hepatology, and 8 9 Nutrition, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai 200062, China 10 **Abstract** 11 Background: The epidemic of 2019 novel coronavirus (COVID-19) struck China in 12 13 late December, 2019, resulting in about 200000 deaths all over the world. Numerous 14 observational studies have suggested that the neutrophil-to-lymphocyte ratio (NLR) and lymphocyte proportion and the platelet-to-lymphocyte ratio (PLR) are 15 inflammatory markers. Our study aimed to detect the role of NLR, PLR in predicting 16 the prognosis of COVID-19. 17 Methods: Four hundred and fifteen consecutive patients were enrolled in Shanghai 18 19 Public Health Clinical Center affiliated to Fudan University, between 20 January and 11 April 2020 with confirmed COVID-19. Epidemiology, symptoms, signs, and 20 laboratory examinations during the hospital stay were collected and compared 21 22 between non-severe and severe patients. Statistical analysis was performed by SPSS 25.0 software. 23 Results: Four hundred and fifteen laboratory-confirmed COVID-19 patients were 24 included in our study, among which 386 (93%) patients were not severe, and 27 (7%) 25 were severe. The proportion of males in severe cases is higher than in non-severe 26 27 cases (75.86% vs. 50.52%, P=0.008). The age between the two groups is different 28 NOTEPTIO DEDIN GEOTS DANGE CANTILLA CLASSON CONTROL OF THE CONT

- comorbidities, including hypertension (48.28% vs. 19.43%, p<0.001), diabetes
- 30 (20.69% vs. 6.99%, p=0.009), chronic obstructive pulmonary disease (51.72% vs.
- 31 6.22%, p<0.001), and fatty liver (37.93% vs. 15.8%, p=0.002), respectively. NLR and
- 32 PLR showed significant difference (p<0.001). Diabetes (OR 0.28; 95% CI
- 33 15.824-187.186), fatty liver (OR 21.469; 95% CI 2.306-199.872), coronary heart
- 34 disease (OR 18.157; 95% CI 2.085-158.083), NLR (OR 1.729; 95% CI 1.050-2.847)
- were significantly associated with severe cases with COVID-19. The NLR of patients
- in severe group had a 1.729-fold higher than that of no-severe group (OR 1.729; 95%)
- 37 CI 1.050-2.847, P=0.031).
- 38 Conclusions: NLR is an independent risk factor of severe COVID-19 patients. PLR,
- 39 NLR were significantly different between severe and non-severe patients, so
- assessment of NLR, PLR may help identify high risk cases with COVID-19.
- 41 **Key words:** Neutrophil-to-lymphocyte ratio, Platelet-to-lymphocyte ratio, COVID-19,
- 42 Severity

43 Introduction

- The epidemic of 2019 novel coronavirus (COVID-19) struck China in late
- December, 2019. A novel coronavirus was then identified as the causative agent.
- 46 Many countries and territories have been affected within two months[1-3]. As of April
- 47 26, 2020, nearly 3,000,000 confirmed cases of COVID-19 occurred, resulting in about
- 48 200000 deaths. Many cases were mild to moderate with common symptoms at onset
- 49 of illness, including fever, cough, and fatigue or myalgia. Organ dysfunction included
- acute respiratory distress syndrome (ARDS), acute liver injury, acute cardiac injury,
- acute kidney injury, and death could occur in the severe cases[4]. In our study, we
- focused on patients with COVID-19 in Shanghai, describing the clinical
- 53 characteristics and prognostic factors.
- Blood cell interactions are essential in the pathophysiology of inflammation,
- immune responses, hemostasis, and oncogenesis. Numerous observational studies
- have suggested that the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to
- 57 monocyte ratio (LMR), lymphocyte proportion and the platelet-to-lymphocyte ratio
- 58 (PLR) are inflammatory markers of immune-mediated, metabolic, prothrombotic, and

60

61

62

63

64

65

66

67

68

69

70

71

72

73 74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

neoplastic diseases, and are widely investigated as useful predictors for prognosis in many diseases [5-7]. These interactions are multifaceted, and it is often difficult to distinguish primary triggering signals and the specific roles of each cell type in the development and progression of disease states. Recent researches of COVID-19 indicated severe patients tended to have higher NLR[8, 9]. Our study aimed to detect the role of NLR, PLR, LMR in predicting the prognosis of COVID-19. **Material and Methods** 1.Study Cohort and Design We recruited 415 consecutive patients in Shanghai Public Health Clinical Center affiliated to Fudan University (the designated hospital in the Shanghai area), between 20 January and 11 April 2020 with confirmed COVID-19. Epidemiology, symptoms, signs, laboratory examinations, chest computerized tomography (CT) scan, and treatment options during the hospital stay were all collected and compared between non-severe and severe patients. This study was approved by the Medical Ethics Committee of Shanghai Public Health Clinical Center affiliated to Fudan University. 2. Statistical Analysis Statistical analysis was performed by SPSS 25.0 software. All data of the demographic and clinical characteristics were expressed as frequencies and proportions for categorical variables, mean SD or median and interquartile (IQR) for continuous variables. We used the one-way ANOVA for categorical variables and the Mann-Whitney U test for continuous variables. To look at risk factors of severe COVID-19, laboratory values were compared with non-severe and severe patients. Then binary logistic regression analysis was used to analyze the risk factors. A P value of <0.05 was considered to be statistically significant. Results **Demographic and Epidemiological features** 415 laboratory-confirmed COVID-19 patients were enrolled in our study, among which 386 (93%) patients were not severe, and 27 (7%) were severe. The demographic, and epidemiologic features on admission were shown in Table 1. Most patients were ethnic Chinese (393/415, 94.7%). The median age of patients was 44

years (IQR 30-61), ranged from 15 years to 84 years. About a half (217, 52.3%) of all 89 90 patients were male. 220 (53%) patients developed COVID-19 due to contacting with Wuhan, Hubei Province, and 27(6.5%) were imported cases. 91 92 Clinical characteristics 93 As showed in Table 2, the proportion of males in severe cases is higher than in non-severe cases (75.86% vs. 50.52%, P=0.008). The age between the two groups is 94 different (p=0.022). Compared with non-severe patients, severe patients exhibited 95 96 more comorbidities, including hypertension (48.28% vs. 19.43%, p<0.001), diabetes (20.69% vs. 6.99%, p=0.009), chronic obstructive pulmonary disease (51.72% vs. 97 6.22%, p<0.001), and fatty liver (37.93% vs. 15.8%, p=0.002), respectively. Only one 98 patient had HIV infection. 22(5.3%) patients had HBV infection and no significant 99 100 difference was found between non-severe and severe cases. Among all these cases, 95.34% of the non-severe group were not smokers, which is similar with severe group 101 of 89.66%. Only 3.11% of non-severe cases had drinking history, and the severe cases 102 of 6.9%. For the virus clearance, there were 15 patients (3.89%) showed that the 103 104 intestinal clearance is later than that of the respiratory. Patients with COVID-19 were treated with different drugs. From our data, 105 patients with severe COVID-19 treated with antiviral medications, interferon 106 atomization, antibiotics, blood product, systemic corticosteroids, and low molecular 107 108 weight heparin, which were significantly higher rate than that in the patients with 109 no-severe COVID-19 (P<0.05). **Laboratory Findings** 110 The laboratory findings were summarized in Table 3 and Table 4. Many patients 111 112 had hematologic abnormalities on admission: anemia (hemoglobin level< 120 g/L) in 13.5% of patients, leukopenia (leukocyte count <4 ×10°cells/L) in 23.9%, 113 lymphopenia (lymphocyte count<1 ×10⁹ cells/L) in 38.8%, and high monocyte 114 percentage (>10%) in 11.5%. The prothrombin time was prolonged (>14 seconds) in 115 the 5.8% of patients. Alanine aminotransferase (>40U/L) were exhibited in 17.5% of 116 the patients, and 54.3% of the patients had elevated C-reactive protein levels (>6 117

118

mg/L).

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

Our study discovered that the white blood cell (WBC) counts on admission of the severe and non-severe cases had no significant difference (P=0.082). Neutrophil counts were significantly higher in severe cases than non-severe cases (P<0.05). Whereas lymphocyte counts were significantly lower in severe cases $(0.88 \times 10^9/L)$ than non-severe cases $(1.12 \times 10^9/L)$. The monocyte percentage was also different between the 2 groups (P=0.015). Severe patients had lower hemoglobin level than that of non-severe patients (P=0.017). NLR, LMR and PLR were compared with severe and non-severe cases, among which NLR and PLR were significant different (P<0.001). Compared with non-severe cases, inflammation-related marker levels (CRP, ESR) were significantly higher in severe cases (P<0.05). The levels of procalcitonin, NT-proB-type natriuretic peptide (NT-proBNP), d-dimer, FDP, albumin, lactate dehydrogenase (LDH), total bilirubin, conjugated bilirubin, CK-MB were elevated in all patients, and significant difference was found between non-severe and severe groups (P<0.05). 4. Analysis with LDH, NLR, LMR and PLR To further define the value of the inflammatory-related parameters in predicting clinical outcomes in COVID-19 patients, the optimal cut-off values for preoperative LDH, NLR, LMR, and PLR that best predicted were calculated as followed: 290.5 (area under the curve (AUC): 0.728; sensitivity: 65.5%; specificity: 88.8%), 3.5 (AUC: 0.764; sensitivity: 72.4%; specificity: 75.1%), 3.0 (AUC: 0.608; sensitivity: 70.0%; specificity: 63.9%), and 222.5 (AUC: 0.659; sensitivity: 48.3%; specificity: 82.6%), respectively (Fig. 1A-D). Then, the patients were dichotomized into high or low LDH/NLR/PLR/LMR groups with these cut-off values. We found that there were significant differences in LDH, NLR and PLR between severe and non-severe groups. (P<0.001). 5. Risk factors for severe cases In the logistic regression model, variables such as diabetes (OR 0.28; 95% CI 15.824-187.186), fatty liver (OR 21.469; 95% CI 2.306-199.872), coronary heart disease (OR 18.157; 95% CI 2.085-158.083), NLR (OR 1.729; 95% CI 1.050-2.847)

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

were significantly associated with severe cases with COVID-19, while ESR is a protective factor (OR 0.949; 95% CI 0.940-0.999) for no-severe patients (Table 5). The forecast accuracy is 96.6%. In order to better diagnose severe COVID-19, we use the ROC curves to calculate the optimal cut-off values for the combined predictive indicator and other risk factors (Figure 2). The combined predictive indicator which is formulated by logistic regression models, is superior to any single indicator in predicting severe patients. **Discussion** Nowadays, COVID-19 outbreak has caused widespread concern and threatened the global public health security. This retrospective cohort study included 415 COVID-19 patients, among which 29 (7%) were severe. This is different from reports from Wuhan, China[2, 10]. The clinical, laboratory, and radiographic features in this cohort of patients with COVID-19 in Shanghai were nonspecific and similar to those in other series[1-4, 11, 12]. Recently, the epidemics has transmitted from the first stage, in which imported cases composed of the main laboratory-confirmed cases in Shanghai. Compared with patients who had non-severe COVID-19, patients with severe COVID-19 had lower lymphocyte percentage, lymphocyte counts, monocyte percentage, and higher neutrophil percentage, neutrophil counts at presentation. These patients may have had a higher viral load at presentation, which may have led to the apparently worse of laboratory values. We also compared NLR and PLR, the two groups have significantly differences. This probably due to their viral load and immune state. Lactate dehydrogenase, C-reactive protein (CRP), and D-dimer, prothrombin time, FDP, BNP were higher in severe groups than in non-severe groups. From Guang Chen's research, they found that the SARS-CoV-2 infection may affect primarily T lymphocytes particularly CD4+T and CD8+ T cells, resulting in decrease in all numbers as well as IFN-y production[11]. Our data analyzed these immune markers in order to find the cause of severity of COVID-19. In this cohort, we observed that 66.0% of the patients had at least one underlying disorder (i.e., hypertension, diabetes, coronary heart disease), and a higher percentage

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

of hypertension and fatty liver in the severe cases than the non-severe individuals, in consistent with other studies[12, 13]. The risk factors for severity included age, high LDH level, and high d-dimer level in previous reports[8]. However, different from the findings of previous studies, we found coronary heart disease and fatty liver were the comorbidity associated with the severity of COVID-19. The NLR was higher in severe cases than in non-severe cases which is consistent with recent studies [8, 9]. Besides, we found PLR was also higher in severe patients compared with non-severe patients. Numerous observational studies have suggested that the NLR, LMR, lymphocyte proportion and the PLR are inflammatory markers of immune-mediated, metabolic, prothrombotic, and neoplastic diseases, and are widely investigated as useful predictors for prognosis in many diseases[5-7]. The results of this study have several clinical implications and strengths. Since NLR and PLR could be quickly calculated based on a blood routine test on admission, so we should pay attention to these laboratory findings to identify high risk COVID-19 patients. Recent researches focus on asymptomatic infection[14, 15], possible fecal-oral transmission in SARS-Cov-2 infection[16], and positive result for SARS-Cov-2 test in recovered patients[17]. At the same time, some reports discussed some COVID-19 patients with underlying disorders, such as diabetes[18], cancer[19] and so on. As we all know, people around the world should pay attention to this disease. There are some limitations in our study. First, the number of observed events is to some extent small which may limit the statistical power of this research. However, the sample size is sufficient to draw a conclusion. Second, in our group, there were fewer severe patients which may not balance for analysis. Third, the causal relationship between abnormal laboratory findings and severity could not be estimated since laboratory findings were measured on admission and may not indicate the severity of COVID-19.

Table 1. Demographic and Epidemiologic Characteristics of Patients

with COVID-19

| Characteristics | All patients, | Patients with non-severe | Patients with severe |
|--------------------------------------|--------------------|--------------------------|----------------------|
| | (n=415) | COVID-19 (n=386) | COVID-19 (n=29) |
| Demographic | | | |
| Median age (range), y | 44(30-61) | 41(30-59) | 64.5(62.25-74.75) |
| Men/women, <i>n/n</i> | 217/198 | 195/191 | 22/7 |
| BMI | 23.61(21.24-25.95) | 23.51(21.13-25.95) | 24.22(22.45-27.54) |
| Ethnicity, n | | | |
| Ethnic Chinese | 393 | 364 | 29 |
| Non-Chinese | 22 | 22 | 0 |
| Recent travel to areas with COVID-19 | | | |
| outbreak, n | | | |
| Hubei Province | 220 | 204 | 16 |
| Wenzhou, Zhejiang Province | 2 | 2 | 0 |
| Outside China | 27 | 26 | 1 |

Table 2. Clinical Features of Patients with COVID-19

| 240 | | | |
|----------------------------|--|--------------------------------------|---------|
| Variables | Patients with non-severe COVID-19 (n= 386) | Patients with severe COVID-19 (n=29) | P value |
| Gender | | • • • | |
| Male | 195(50.52%) | 22(75.86%) | 0.008 |
| Female | 191(49.48%) | 7(24.14%) | |
| Age, years | | | |
| 0-44 | 221(57.25%) | 10(34.48%) | 0.022 |
| 45-64 | 118(30.57%) | 16(55.17%) | |
| ≥65 | 47(12.18%) | 3(10.34%) | |
| Underlying diseases, n (%) | | | |
| Hypertension | | | |
| No | 311(80.57%) | 15(51.72%) | < 0.001 |
| Yes | 75(19.43%) | 14(48.28%) | |
| Diabetes | | | |
| No | 359(93.01%) | 23(79.31%) | 0.009 |
| Yes | 27(6.99%) | 6(20.69%) | |
| AIDS | | | |
| No | 385(99.74%) | 29(100%) | 0.784 |
| Yes | 1(0.26%) | 0(0%) | |
| HBV | | | |
| No | 366(94.82%) | 27(93.1%) | 0.691 |
| Yes | 20(5.18%) | 2(6.9%) | |
| СНД | | | |
| No | 362(93.78%) | 14(48.28%) | < 0.001 |
| Yes | 24(6.22%) | 15(51.72%) | |
| FLD | | | |
| No | 325(84.2%) | 18(62.07%) | 0.002 |
| Yes | 61(15.8%) | 11(37.93%) | |
| Smoking history, n (%) | | | |
| No | 368(95.34%) | 26(89.66%) | 0.179 |
| Yes | 18(4.66%) | 3(10.34%) | |
| Drinking history, n (%) | | | |
| No | 374(96.89%) | 27(93.1%) | 0.276 |
| Yes | 12(3.11%) | 2(6.9%) | |
| CT evidence of pneumonia | | | |
| No | 328(84.97%) | 26(89.66%) | 0.493 |
| Yes | 58(15.03%) | 3(10.34%) | |

| Supportive treatment, n (%) | | | |
|---|-------------|------------|--------|
| Administration of antiviral medications | | | |
| No | 59(15.28%) | 1(3.45%) | 0.081 |
| Yes | 327(84.72%) | 28(96.55%) | |
| Administration of interferon atomization | | | |
| No | 286(74.09%) | 10(34.48%) | <0.001 |
| Yes | 100(25.91%) | 19(65.52%) | |
| Administration of antibiotics | | | |
| No | 288(74.61%) | 0(0%) | <0.001 |
| Yes | 98(25.39%) | 29(100%) | |
| Administration of systemic corticosteroids | | | |
| No | 364(94.3%) | 3(10.34%) | <0.001 |
| Yes | 22(5.7%) | 26(89.66%) | |
| Use of blood products | | | |
| No | 367(95.08%) | 4(13.79%) | <0.001 |
| Yes | 19(4.92%) | 25(86.21%) | |
| Use of low molecular weight heparin | | | |
| No | 368(95.34%) | 4(13.79%) | <0.001 |
| Yes | 18(4.66%) | 25(86.21%) | |
| Use of sedative | | | |
| No | 351(90.93%) | 12(41.38%) | <0.001 |
| Yes | 35(9.07%) | 17(58.62%) | |
| Virus clearance (Intestinal later that respiratory) | an | | |
| No | 371(96.11%) | 29(100%) | 0.28 |
| Yes | 15(3.89%) | 0(0%) | |

²⁴¹ Abbreviation: AIDS, Acquired Immune Deficiency Syndrome; HBV, hepatitis B

virus; CHD, Coronary Heart Disease; FLD, Fatty Liver Disease.

Table 3. Laboratory Findings of Patients with COVID-19

| Laboratory Finding | Patients with non-severe | Patients with severe | P value | |
|--|--------------------------|-----------------------|---------|--|
| | COVID-19(n=321) | COVID-19(n=27) | | |
| Leukocyte count, ×10° cells/L | 4.68(3.73-5.66) | 6.24(4.47-7.74) | 0.082 | |
| Neutrophil, % | 63.29±11.44 | 72.48±13.70 | 0.001 | |
| Neutrophil count, ×10° cells/L | 2.85(2.28-3.79) | 4.06(3.26-6.42) | 0.004 | |
| Lymphocyte, % | 24.50(20.6-31.9) | 15.5(5.9-21.6) | < 0.001 | |
| Lymphocyte count, ×10° cells/L | 1.12(0.82-1.49) | 0.88(0.45-1.22) | 0.001 | |
| Monocyte, % | 9.5(7.3-11.3) | 7.2(4.0-13.6) | 0.015 | |
| Monocyte count, ×10 ⁹ cells/L | 0.41(0.35-0.58) | 0.50(0.24-1.07) | 0.157 | |
| Hemoglobin level, g/L | 138.29±16.15 | 129.86±29.99 | 0.017 | |
| Hematokrit, % | 40.21±4.35 | 38.92±4.20 | 0.143 | |
| Platelet count, ×109 cells/L | 177(143-220) | 155(117-189.5) | 0.455 | |
| C-reactive protein level, mg/L | 6.06(0.499-18.45) | 70.74(31.02-103.77) | < 0.001 | |
| ESR, mm/60min | 48(25-89) | 82(42.5-110.5) | 0.027 | |
| Prothrombin time, s | 13.5(13.0-13.8) | 13.9(12.85-15.55) | 0.266 | |
| FDP | 0.88(0.39-1.47) | 2.42(1.29-20.25) | 0.006 | |
| D-dimer | 0.43(0.24-0.57) | 0.89(0.57-5.26) | <0.001 | |
| BNP | 29.41(21.05-46.28) | 133.30(56.38-504.4) | 0.005 | |
| Procalcitonin, ng/mL | 0.03(0.02-0.05) | 0.14(0.07-0.35) | <0.001 | |
| Alanine aminotransferase level, U/L | 20(14-34) | 25(14-37) | 0.289 | |
| Albumin level, g/L | 41.71±4.59 | 36.61±5.94 | <0.001 | |
| Globulin level, g/L | 28.22(25.9-30.91) | 27.95(25.22-31.35) | 0.06 | |
| Creatinine | 64.48(51.73-74.36) | 66.87(56.30-80.93) | 0.149 | |
| eGFR | 112.16(95.74-131.56) | 99.70(81.31-117.08) | 0.166 | |
| CK-MB | 11.31(9.68-15.13) | 14.42(10.86-20.58) | 0.003 | |
| Total blirubin level, mmol/L [mg/dL] | 8.2(6.3-13.8) | 10.3(6.95-15.0) | 0.049 | |
| Lactate, mmol/L | 2.67(2.31-3.07) | 2.50(2.31-3.64) | 0.534 | |
| Lactate dehydrogenase level, U/L | 214(190-268) | 399(278-537) | <0.001 | |
| NLR | 2.67(1.76-3.42) | 4.16(3.14-14.65) | <0.001 | |
| LMR | 2.73(1.84-3.66) | 1.92(0.51-3.13) | 0.052 | |
| PLR | 145.64(119.87-196.68) | 180.68(110.56-457.96) | 0.004 | |

Table 4. Laboratory Findings of Patients with COVID-19

| Laboratory Finding | Patients with non-severe | Patients with severe | P value |
|----------------------------------|--------------------------|----------------------|---------|
| | COVID-19(n=321) | COVID-19(n=27) | |
| Lactate dehydrogenase level, U/L | | | |
| ≤290.5 | 315(81.82%) | 10(34.48%) | <0.001 |
| >290.5 | 70(18.18%) | 19(65.52%) | |
| NLR | | | |
| ≤3.5 | 289(74.87%) | 8(27.59%) | <0.001 |
| >3.5 | 97(25.13%) | 21(72.41%) | |
| LMR | | | |
| ≤3.0 | 209(54.15%) | 19(65.52%) | 0.236 |
| >3.0 | 177(45.85%) | 10(34.48%) | |
| PLR | | | |
| ≤222.5 | 318(82.38%) | 15(51.72%) | <0.001 |
| >222.5 | 68(17.62%) | 14(48.28%) | |

Table 5. Risk factors for severe cases

| Variables | P | OR | 95% CI for OR | |
|-----------|-------|--------|---------------|---------|
| | | | Lower | Upper |
| Diabetes | 0.028 | 15.824 | 1.338 | 187.186 |
| FLD | 0.007 | 21.469 | 2.306 | 199.872 |
| CHD | 0.009 | 18.157 | 2.085 | 158.083 |
| NLR | 0.031 | 1.729 | 1.050 | 2.847 |
| ESR | 0.043 | 0.969 | 0.940 | 0.999 |




Fig. 1 The cut-off values for the inflammation-related parameters. A-D. ROC curves were adopted to calculate the cut-off values for LDH(A), NLR (B), LMR (C), and PLR(D). LDH, lactate dehydrogenase, NLR, neutrophil-to-lymphocyte ratio, LMR, lymphocyte-to-monocyte ratio, PLR, platelet-to-lymphocyte ratio, AUC, area of under curve.




Fig. 2 The combined predictive indicator and other risk factors for ROC curves. NLR, neutrophil-to-lymphocyte ratio, ESR, erythrocyte sedimentation rate.

References

274

- Chang, et al., Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections
 Involving 13 Patients Outside Wuhan, China. JAMA, 2020.
- 277 2. Chen, N., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel
- 278 coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020. 395(10223): p.
- 279 507-513.
- 280 3. Li, Q., et al., Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med, 2020.
- 282 4. Zhu, N., et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med, 2020. 382(8): p. 727-733.
- 5. Gasparyan, A.Y., et al., *The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases.* Ann Lab Med, 2019. **39**(4): p. 345-357.
- 286 6. Ha, Y.J., et al., Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict 287 survival in patients with adult polymyositis and dermatomyositis: A retrospective 288 observational study. PLoS One, 2018. **13**(1): p. e0190411.
- Ying, H.Q., et al., The prognostic value of preoperative NLR, d-NLR, PLR and LMR for
 predicting clinical outcome in surgical colorectal cancer patients. Med Oncol, 2014. 31(12): p.
 305.
- 292 8. Liu, Y., et al., Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect, 2020.
- Qin, C., et al., Dysregulation of immune response in patients with COVID-19 in Wuhan, China.
 Clin Infect Dis, 2020.
- 296 10. Li, X., et al., *Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan.* J Allergy Clin Immunol, 2020.
- 298 11. Chen, G., et al., Clinical and immunologic features in severe and moderate Coronavirus 299 Disease 2019. J Clin Invest, 2020.
- Tian, S., et al., Characteristics of COVID-19 infection in Beijing. J Infect, 2020. **80**(4): p. 401-406.
- Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020. **395**(10223): p. 497-506.
- 304 14. Corman, V.M., et al., SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission. Transfusion, 2020.
- Hu, Z., et al., Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci, 2020. **63**(5): p. 706-711.
- 308 16. Chan, J.F., et al., A familial cluster of pneumonia associated with the 2019 novel coronavirus 309 indicating person-to-person transmission: a study of a family cluster. Lancet, 2020. 310 395(10223): p. 514-523.
- 311 17. Lan, L., et al., Positive RT-PCR Test Results in Patients Recovered From COVID-19. JAMA, 312 2020.
- 313 18. Flint, S.W. and A.A. Tahrani, *COVID-19 and obesity-lack of clarity, guidance, and implications for care.* Lancet Diabetes Endocrinol, 2020.
- Yu, J., et al., SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in
 Wuhan, China. JAMA Oncol, 2020.